Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

VXRT

Vaxart (VXRT)

Vaxart Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:VXRT
일자시간출처헤드라인심볼기업
2024/05/1405:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VXRTVaxart Inc
2024/05/1405:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
2024/05/1405:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:VXRTVaxart Inc
2024/05/1320:10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:VXRTVaxart Inc
2024/05/0721:00GlobeNewswire Inc.Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13NASDAQ:VXRTVaxart Inc
2024/04/3021:00GlobeNewswire Inc.Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating MothersNASDAQ:VXRTVaxart Inc
2024/03/2721:00GlobeNewswire Inc.Vaxart to Present at World Vaccine Congress Washington 2024 on April 3NASDAQ:VXRTVaxart Inc
2024/03/2021:00GlobeNewswire Inc.Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VXRTVaxart Inc
2024/03/1505:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:VXRTVaxart Inc
2024/03/1420:41IH Market NewsU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices ClimbNASDAQ:VXRTVaxart Inc
2024/03/0722:00GlobeNewswire Inc.Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14NASDAQ:VXRTVaxart Inc
2024/03/0623:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
2024/03/0622:00GlobeNewswire Inc.Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorNASDAQ:VXRTVaxart Inc
2024/03/0106:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
2024/02/1606:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
2024/02/1407:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VXRTVaxart Inc
2024/02/0522:00GlobeNewswire Inc.Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 ChallengeNASDAQ:VXRTVaxart Inc
2024/02/0306:49Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VXRTVaxart Inc
2024/01/2007:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
2024/01/2006:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VXRTVaxart Inc
2024/01/1922:30GlobeNewswire Inc.Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateNASDAQ:VXRTVaxart Inc
2024/01/1707:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
2024/01/1623:25GlobeNewswire Inc.Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital ManagementNASDAQ:VXRTVaxart Inc
2024/01/1623:22GlobeNewswire Inc.Vaxart, Inc. Announces Management ChangeNASDAQ:VXRTVaxart Inc
2024/01/1623:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
2023/12/2122:00GlobeNewswire Inc.Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersNASDAQ:VXRTVaxart Inc
2023/11/0305:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VXRTVaxart Inc
2023/11/0305:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
2023/11/0305:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:VXRTVaxart Inc
2023/11/0221:00GlobeNewswire Inc.Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersNASDAQ:VXRTVaxart Inc
 검색 관련기사 보기:NASDAQ:VXRT